Advanced Glycation End Products (Ages) and Its Soluble Receptor in Smokers and Mild/Moderate COPD

2016 ◽  
Vol 02 (03) ◽  
Author(s):  
Caram LMO ◽  
Ferrari R ◽  
Rasslan Z
Keyword(s):  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria

2015 ◽  
Vol 13 (2) ◽  
pp. 259-264
Author(s):  
Huan Zheng ◽  
Lingyan Yuan ◽  
Nanzi Xie ◽  
Huifeng Xu ◽  
Xiaoyun Xie ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score

2011 ◽  
Vol 107 (6) ◽  
pp. 938-944 ◽  
Author(s):  
Sergio Raposeiras-Roubín ◽  
Bruno K. Rodiño-Janeiro ◽  
Lilian Grigorian-Shamagian ◽  
María Moure-González ◽  
Ana Seoane-Blanco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Louise J. N. Jensen ◽  
Allan Flyvbjerg ◽  
Mette Bjerre
Keyword(s):  
Acute Coronary Syndrome ◽  
Advanced Glycation End Products ◽  
Acute Ischemia ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Coronary Syndrome ◽  
Potential Biomarker ◽  
Glycation End Products ◽  
End Products ◽  
Artery Disease

The receptor of advanced glycation end products (RAGE) and its ligands are linked to the pathogenesis of coronary artery disease (CAD), and circulating soluble receptor of advanced glycation end products (sRAGE), reflecting the RAGE activity, is suggested as a potential biomarker. Elevated sRAGE levels are reported in relation to acute ischemia and this review focuses on the role of sRAGE as a biomarker for the acute coronary syndrome (ACS). The current studies demonstrated that sRAGE levels are elevated in relation to ACS, however during a very narrow time period, indicating that the time of sampling needs attention. Interestingly, activation of RAGE may influence the pathogenesis and reflection in sRAGE levels in acute and stable CAD differently.

Sign in / Sign up

Export Citation Format

Share Document